Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04800874 · ClinicalTrials.gov registry record · Phase 2
Study of BBP-418 in Patients With LGMD2I
A Phase 2 study of LGMD2I, sponsored by ML Bio Solutions.
- Active
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04800874 is a Phase 2 study of LGMD2I that is active but no longer recruiting, run by ML Bio Solutions. The registered enrollment target is 14 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04800874, a Phase 2 study of LGMD2I, is active but no longer recruiting, sponsored by ML Bio Solutions.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I). This is an open label study to determine the safety and tolerability of ascending dose levels of BBP-418 in the treatment of ambulatory and non-ambulatory patients with LGMD2I for which no approved therapy currently exists.
Conditions Studied
Interventions
- DRUG BBP-418
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04800874
The ClinicalTrials.gov registry entry for NCT04800874 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ML Bio Solutions, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with LGMD2I appearing as the primary indexed condition, and to 1 intervention - of which BBP-418 is the first listed.
NCT04800874 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04800874 about?
NCT04800874 is a clinical study titled "Study of BBP-418 in Patients With LGMD2I". BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I). This is an open label study to determine the safety and tolerability of ascending dose levels of BBP-418 in the treatment of ambulatory and non-ambulatory patients with LGMD2I for which no ...
What is the current status of trial NCT04800874?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2021-02-18. Estimated completion is 2026-11-01.
What conditions does trial NCT04800874 study?
This clinical trial studies the following conditions: LGMD2I.
What interventions are being tested in trial NCT04800874?
The interventions under investigation include: BBP-418 (DRUG).
Who is sponsoring clinical trial NCT04800874?
This trial is sponsored by ML Bio Solutions, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04800874 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for LGMD2I
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.